Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 19/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 19/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 15/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27499526 | 1.00 | ITGA4 (0.56) | ITGA4ITGB1ITGB7ITGB3ITGAV | |
| SCHEMBL918862 | 0.94 | ITGA4 (0.63) | ITGA4ITGB1ITGB7ITGA5 | |
| Firategrast SCHEMBL918399 | 0.94 | ITGA4 (0.54) | ITGA4ITGB1ITGB7 | |
| SCHEMBL19235568 | 0.94 | ITGA4 (0.63) | ITGA4ITGB1ITGB7ITGA5 | |
| Firategrast SCHEMBL12002530 | 0.94 | ITGA4 (0.54) | ITGA4ITGB1ITGB7 | |
| SCHEMBL921279 | 0.93 | ITGB1 (0.55) | ITGA4ITGB1ITGB7ITGB3ITGAV | |
| SCHEMBL919149 | 0.92 | ITGA4 (0.49) | ITGA4ITGB1ITGB7 | |
| SCHEMBL920130 | 0.92 | ITGA4 (0.59) | ITGA4ITGB1ITGB7ITGB3ITGAV | |
| Firategrast SCHEMBL1681763 | 0.92 | ITGA4 (0.53) | ITGA4ITGB1ITGB7 | |
| SCHEMBL27499829 | 0.92 | ITGA4 (0.59) | ITGA4ITGB1ITGB7ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-31 | — | — | US | claimed |
| US-8501809-B2 | Inhibitors of α4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-06 | — | — | US | claimed |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2011-03-31 | — | — | US | claimed |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2009-04-30 | — | — | US | claimed |
| US-7456217-B2 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-11-25 | — | — | US | claimed |
| US-7026501-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2006-04-11 | — | — | US | claimed |
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | claimed |
| CN-1229334-C | α4Inhibitors of mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2005-11-30 | — | — | CN | claimed |
| EP-1315694-B1 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | claimed |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-09-18 | — | — | US | claimed |
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-31 | — | — | US | disclosed |
| US-8501809-B2 | Inhibitors of α4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8410115-B2 | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2011-03-31 | — | — | US | disclosed |
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1229334-C | α4Inhibitors of mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2005-11-30 | — | — | CN | disclosed |
| EP-1315694-B1 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| CN-1449377-A | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2003-10-15 | — | — | CN | disclosed |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | IL4, PSMA4, SCN4A | ITGA4 27/4885ITGB1 277/4885ITGB7 464/4885 |
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | ITGB4, VCAM1, EPCAM | ITGA4 4/4885ITGB1 9/4885ITGB7 59/4885 |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.